Mutation, absence or abnormal functioning of retinoblastoma protein are fundamental elements of uncontrolled growth in human cancer. In this study, we analyze the expression of retinoblastoma protein and phosphorylated retinoblastoma protein in melanocytic tumors in vivo. Real-time RT-PCR and immunohistochemistry (tissue microarrays and conventional histological sections) reveal that retinoblastoma protein is progressively upregulated in advanced and metastatic malignant melanomas in vivo. However, this increase is paralleled by increased retinoblastoma protein inactivation due to protein phosphorylation. Interestingly, retinoblastoma protein phosphorylation occurs not homogeneously, but with a 'growth zone'-related pattern. In superficial spreading melanomas a subepidermal-lateral maximum of phosphorylated retinoblastoma protein can be frequently observed. Accordingly, nodular vertically invasive melanomas are characterized by a strong staining of phosphorylated retinoblastoma protein in deep-dermal invading protrusions of the tumor. Furthermore, Kaplan-Meier analysis of 13 cases of advanced melanomas with long-time follow-up suggests a significant negative impact of retinoblastoma protein phosphorylation on survival of melanoma patients independent of tumor thickness. We conclude that the evaluation of phosphorylated retinoblastoma protein in melanocytic tumors could become a helpful adjunct in clinicopathological routine.
The main principle of cell cycle homeostasis is the phosphorylation-dependent activation and deactivation of regulatory proteins upstream of retinoblastoma protein (pRb), which represents the central cycle-controlling element. At the G1/S transition, the antiproliferative function of active, hypophosphorylated pRb is mediated by its binding capacity to proproliferative transcription factors such as E2F, c-Myc, ATF-2 and c-Abl.
1 Surprisingly, with the exception of retinoblastoma, osteosarcoma and small cell lung carcinoma, the overall rate of pRbmutations in the vast majority of human cancers is either extremely low or not existent. 2 Also in malignant melanomas, the loss of cell cycle control is thought to be due to a lack of pRb activity and not to lack of expression or mutation. 3, 4 Currently, the concept is arguably accepted that persistent inactivation and hyperphosphorylation of wild-type pRb in melanomas is caused by a sustained cyclindependent kinase (cdk) activity. [5] [6] [7] In uveal malignant melanomas, Brantley et al 8, 9 have recently reported an increased pRb phosphorylation at Ser807/811. Since they have also detected a high cyclin D expression, the hypothesis of a functional inactivation of pRb due to cyclin-and cdk-dependent hyperphosphorylation was further substantiated.
To the best of our knowledge, no detailed studies have been performed to elucidate the pRb phosphorylation status in in vivo samples of cutaneous melanocytic tumors. In particular, studies on the impact of hyperphosphorylated pRb on melanoma progression are still lacking. Therefore, in this study we analyze total pRb and phosphorylated pRb expression in tumor biopsies of progressive and nonprogressive melanocytic lesions including common and dysplastic nevi, primary melanomas, melanoma metastases and, as control, further neuroectodermal tumors such as glioblastomas, schwannomas and neurofibromas. To disclose a potential association of the histologically detectable degree of pRb phosphorylation and the prognosis of melanoma patients, a panel of long-term survivors with thick, high-risk primary melanomas (TD43.5 mm) were analyzed with Kaplan-Meier statistics.
Materials and methods

Tissue Samples and RNA Sources
Fresh, uncultured tumor materials of six melanocytic nevi, five primary malignant melanomas and seven melanoma metastases (lymph nodes and cutaneous metastases) were collected. Samples of five glioblastomas were a kind gift from Juergen Schlegel, Department of Neuropathology, TU Munich, Germany. Detailed tumor data of the melanocytic samples and the technical details of microdissection and RNA extraction have been recently published. 10 Control RNAs from nonmelanocytic tissues were obtained from Ambion Inc., Austin/TX, USA and BD Biosciences, Heidelberg, Germany.
Gene Expression Analysis
RT-PCR was performed using the Reverse Transcription Kitt (Promega, MD, USA) according to the recommended protocol. For relative quantitation of transcribed gene-specific RNA, TaqMant real-time RT-PCR (Applied Biosystems, Darmstadt, Germany) was performed as described. 11, 12 Primers and probe for Rb-mRNA detection were purchased from Applied Biosystems (Assay on demandt, Applied Biosystems, Darmstadt, Germany). Primers and probe for 18s rRNA served as endogenous controls using the corresponding predesigned assay (also Applied Biosystems). For each sample, triplicate reactions were performed. Relative expression ratios were calculated using a standard curve generated with Human Reference RNA (Stratagene, La Jolla, USA), which contains pooled RNAs from 11 different tumor cell lines. 10 
Tissue Microarrays
According to the method established by Kononen et al 
Immunohistochemistry
Tissue microarrays and conventional paraffinembedded tissue sections were prepared according to standard protocols and subsequently incubated with a 1:100 dilution of the primary antibody for 30 min at room temperature. For total pRb detection, Rb (4H1) Monoclonal antibody was obtained from Cell Signaling Technology/New England Biolabs GmbH, Frankfurt, Germany. For detection of phosphorylated pRb, we used Phospho-Rb (Ser795), Phospho-Rb (Ser780) and Phospho-Rb (Ser807/811) antibodies from the same manufacturer. To avoid experimental bias within the set of tumor samples, immunohistochemistry of all examined tissue samples was performed under identical experimental conditions.
Immunohistochemical Evaluation of Total pRb and Phosphorylated pRb (p-pRb) Expression Using Tissue Microarrays
Tissue microarrays were examined to proof gross constitutive differences in pRb-and p-pRb-expression between 'full scale' malignant melanocytic tumors (metastases) and benign. To reduce bias, immunostaining was assessed by two independent investigators in a blinded fashion. Inter-and intraexaminer reproducibility was 92 and 95%, respectively. Immunostaining intensity was scored using uniform and clear cutoff criteria to maintain the reproducibility of the method. Briefly, the result of immunostaining was recorded as negative or positive considering the expression in tumor cells. In case of total pRb, p-pRb Ser780 and p-pRb Ser795, samples were classified as positive if more than 10% of the tumor cells achieved higher signals than the internal positive controls (stratum germinativum of the epidermis). Since p-pRb Ser807/811-staining appeared comparably low, the threshold was set to 5% positively stained tumor cells.
Immunohistochemical Evaluation of Total pRb and Relative p-pRb Expression in 'Whole Tumor'-Tissue Sections
Since the punched samples arrayed on the tissue microarrays may fail to represent possible heterogeneity of pRb/p-pRb expression, complete tumor sections (five papillomatous nevi, four dysplastic nevi, five superficial spreading melanomas, 20 nodular melanomas, five melanoma metastases, five neurofibromas, five schwannomas) were analyzed in a second set of experiments. As it became apparent that the number of stained nuclei and the staining intensity can vary grossly within one tumor, a more complex evaluation algorithm was applied for complete sections. For each sample, three representative fields of vision were evaluated at Â 400 magnification in (a) a region with maximum and (b) a region with minimum staining, respectively. The number of positive-stained nuclei was estimated as percentage of all nuclei (p). In addition, the staining intensities (i) of positive cells were scaled. Cells showing a slight granular staining pattern were graded as 1, whereas cells with completely filled nuclei were graded as 4. Grades 2 and 3 were assigned to intermediate staining intensities. Based on mean staining percentages (p) and intensities (i) of all samples (n) of a given pathologically determined entity expression scores (ES) were calculated for both the regions with maximum and the regions with minimum expression according to the following formula:
where p nx is the mean percentage of stained nuclei of three representative fields of tumor X, i nx the mean staining intensity of three representative fields of tumor X and ES the expression score.
Phosphorylated pRb (p-pRb) and Prognosis
Tissue sections from high-risk nodular melanomas from patients with long-time follow-up information were analyzed concerning the expression of pRb, p-pRb Ser795, p-pRb Ser780 and p-pRb Ser807/811. Five patients with an exceptional long-term survival of more than 5 years despite high tumor thickness (Breslow index Z3.5 mm) were selected from 8000 patients in the local database. In addition, eight matched cases with a more typical average survival of 25.3 months (short-time survival) were considered. The cases were matched for tumor thickness, similar location, same sex of patient and age. This cohort is thought as a model for evaluating prognostic factors that are possibly independent of tumor thickness. A more detailed description of this cohort is given in Vogt et al. 14 For correlation with prognosis, p-pRb of all three antibodies were summarized as p-pRb index for each individual tumor:
where p p is the mean percentage of stained nuclei of three representative fields of a tumor, i i the mean staining intensity of three representative fields of a tumor and p-pRb index the prognostic index.
For this p-pRb index, areas with maximum staining were considered within each section. For subsequent Kaplan-Meier analysis, an empirical threshold of 30.0 was used.
Statistical Analysis
The SPSS 10.0 (SPSS Inc, Erkrath, Germany) software package was used to perform statistical analyses. For assessment of relative mRNA expression levels the nonparametric Mann-Whitney U-test was applied. For assessment of intratumoral differences of protein expression we used the Wilcoxon test for coupled samples. Kaplan-Meier curves were evaluated by a log-rank test. For all statistical tests a probability of error Po0.05 was required.
Results
Rb mRNA Expression in Melanocytic Tumors and Normal Tissues
Relative measurements of Rb mRNA expression in microdissected melanocytic tumor biopsies revealed a significant almost threefold overexpression of Rb mRNA in malignant melanomas (n ¼
05).
In contrast, expression levels of various non-neuroectodermalmalignant control tissues (mRNAs from lung carcinoma, breast carcinoma, colon carcinoma) showed uniformly low expression levels. Interestingly, a similar trend of Rb mRNA overexpression was also detected in glioblastomas, which served as independent controls derived from a different entity of neuroectodermal cancer. In glioblastomas (n ¼ 5) the Rb mRNA expression also exceeded the mRNA levels of normal tissue (fetal and adult brain) twoto threefold (Figure 1 ).
Immunohistochemical Staining of Total pRb and Phosphorylated pRb (p-pRb Ser780, Ser795 and Ser807/811) Using Tissue Microarrays
In accordance with our RT-PCR data, tissue microarray-based immunohistochemistry confirmed gross constitutive differences in the pRb-expression between melanocytic nevi (n ¼ 60) and melanoma metastases (n ¼ 60) (Figure 2 ). Interestingly at Ser795, we found an almost complete phosphorylation of the progressively overexpressed total pRb, whereas in melanocytic nevi only a fraction of total pRb was phosphorylated. Phosphorylation at Ser807/811 generally occurred to a lesser extent, but significantly higher in melanoma metastases compared to melanocytic nevi. In case of Ser780, no significant differential phosphorylation between nevi and metastases was detectable.
Immunohistochemical Staining of Total pRb and p-pRb in Sections with Preserved Tumor Architecture
In order to analyze possible intratumoral heterogeneity that may be missed by tissue microarrays due to limited punch size, we also analyzed sections with preserved full tumor architecture. Expression scoring for total pRb in complete tumor sections was in support of our RT-PCR results, that is, a progressive increase of pRb in malignant melanocytic tumors (details are given in Table 1 and Figure 3 ). Comparing expression scores from complete sections with tissue microarray-based results, the progressive increase in phosphorylation could be confirmed for all three phospho sites analyzed. And, as we have already suggested from the tissue microarrays, Ser795 reached the highest expressions scores in metastases. In primary melanomas both Ser780 and Ser795 were typically phosphorylated. Furthermore, the complete tissue sections did reveal a considerable intratumoral heterogeneity of total pRb expression. In superficial spreading melanomas, subepidermal vs dermal ES were significantly different with the most intense staining result in the subepidermal-lateral portions (Po0.005). In nodular malignant melanomas, the invasive part vs tumor center (Po0.001) and in melanoma metastases outer margins vs centers (Po0.003) also showed significant differences (Table 1 ). Other benign neuroectodermal tumors that served as independent controls such as schwannomas and neurofibromas showed a comparably low 'melanocytic nevus-like' pRbexpression with no significant intratumoral heterogeneity (not shown). Accordingly, p-pRb typically showed a subepidermal-lateral maximum of staining scores in superficial spreading melanomas (Figure 3g -i) and in deep-dermal invading protrusions of nodular malignant melanomas (Figure 3j-l) . In melanoma metastases, an accumulation of p-pRb staining was mainly detected in the outer margins Figure 2 Tissue microarray-based evaluation of total pRb-and phosphorylated pRb (p-pRb) Ser795/Ser780/Ser807/811-expression in 60 melanocytic nevi vs 60 melanoma metastases. Depicted are percentages of positive (410% of the nuclei stained) and negative samples (o10% of the nuclei stained) as well as bad quality spots. At Ser795, an almost complete phosphorylation of the progressively overexpressed total pRb is found. Phosphorylation at Ser807/811 occurred to a lesser extent, but significantly higher in melanoma metastases compared to melanocytic nevi. In case of Ser780, no significant differential phosphorylation between nevi and metastases was detectable.
Overexpression and hyperphosphorylation of retinoblastoma protein
A Roesch et al compared to the tumor center. In contrast, in benign and dysplastic nevi as well as schwannomas/ neurofibromas pRb phosphorylation was almost negligible (Table 1) .
pRb Phosphorylation and Prognosis
We found a clear trend to higher p-pRb indices in short-time survivors vs exceptional long-time survivors in our cohort of matched survivors and nonsurvivors with high Breslow-indices (tumor thickness 43.5 mm) (Table 2, Figure 4) . Using an arbitrary threshold of 30.0 as discriminating factor in Kaplan-Meier statistics, low p-pRb indices (o30.0) were significantly correlated with a prolonged survival, whereas high p-pRb indices (430.0) were correlated with early death (log-ranktest P ¼ 0.03). This suggests a possible Breslow-(tumor thickness)-independent prognostic impact of pRb-phosphorylation.
Discussion
In this study, we can confirm for the first time by two independent methods, real-time RT-PCR and immunohistochemistry, that (i) in cutaneous malignant melanocytic tumors total Rb-expression is progressively upregulated and that (ii), simultaneously, augmented total pRb is probably functionally inactive due to protein hyperphosphorylation. Interestingly, a particularly high degree of pRbphosphorylation can be observed in tumor regions with expansive growth activity, that is, the deep invasive front of the vertical growth phase of nodular melanomas and the lateral-subepidermal parts of superficial spreading melanomas. Accordingly, the benign counterparts analyzed (melanocytic nevi, schwannomas, neurofibromas) show a moderate, mostly homogeneous expression of pRb and pRb-phosphorylation. Concerning pRb expression in malignant melanomas, partly conjectural data have been reported in the past. Korabiowska et al 15 postulated a downregulation of total pRb during melanoma progression. In contrast, Maelandsmo et al 16 and Saenz-Santamaria et al 17 reported about a significant upregulation of pRb in primary and metastatic melanomas. Based on latter findings, it was suggested that pRb-mutations or a lack of expression probably play a subordinate role in melanoma. It was further speculated that the reduction of pRb-activity due to hyperphosphorylation could be a causal principle of unlimited growth of melanoma. 3, 4 To the best of our knowledge, this is the first report on p-pRb in in vivo samples of cutaneous malignant melanomas. Employing currently available phosphorylation site-directed antibodies, we have analyzed three out of 16 possible phosphorylation sites of pRb. p-pRb Ser795 showed the best In contrast to Ser795, Ser780 and Ser807/811 are exclusively phosphorylated by CDK4-D. 1, 19, 20, 22 Interestingly Ezhevsky et al 23 reported that CDK4-D-mediated phosphorylation of pRb is a prerequisite for the transition of unphosphorylated inactive pRb into hypophosphorylated active pRb. This suggests that the increase in pRb phosphorylation at Ser780 detected in benign nevi represents active cell cycling suppressing pRb. Therefore, it could be worthwhile to further unravel the details of the phosphorylation status of all pRb phosphorylation sites in melanoma. However, currently the usefulness and practical value of a diversified analysis of all phosphorylation residues of pRb remains elusive due to limited availability of suitable antibodies. Nevertheless, the status of the three phosphorylation sites analyzed seems to harbor potentially prognostic information, possibly independent of tumor thickness. To date, tumor thickness is considered as the most valid prognostic factor in melanomas and within certain limits an almost linear correlation between tumor thickness and metastatic risk has been demonstrated. 24 However, recent studies on several thousands of patients 24 also delineate limitations of tumor thickness used as single predictor. In particular, if the tumor thickness exceeds 3.5 mm, it loses predictive power. 25 We conclude that in neuroectoderm-derived cancers, melanocytic tumors and glioblastomas, overexpression of the cell cycle controller pRb is limited to the malignant phenotype. pRb is markedly overexpressed in actively growing parts of malignant melanomas and coincident with hyperphosphorylation and possible pRb inactivation. Since p-pRb content seems correlated with prognosis, evaluation of p-pRb status in melanocytic tumors could, therefore, become a helpful adjunct in clinicopathological routine. 
